PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.72%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
-21.99%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
32.68%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
32.51%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
32.51%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-20.05%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-102666.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-29000.87%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
0.57%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-765363.95%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-27613.67%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-208.91%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
82516.86%
10Y equity/share CAGR above 1.5x AXSM's 930.62%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5226.69%
5Y equity/share CAGR above 1.5x AXSM's 930.62%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1660.30%
3Y equity/share CAGR above 1.5x AXSM's 930.62%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-32.96%
We’re deleveraging while AXSM stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
44.99%
R&D dropping or stable vs. AXSM's 105.00%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.08%
We cut SG&A while AXSM invests at 43.31%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.